JP2010510323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510323A5 JP2010510323A5 JP2009538506A JP2009538506A JP2010510323A5 JP 2010510323 A5 JP2010510323 A5 JP 2010510323A5 JP 2009538506 A JP2009538506 A JP 2009538506A JP 2009538506 A JP2009538506 A JP 2009538506A JP 2010510323 A5 JP2010510323 A5 JP 2010510323A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- composition according
- effective amount
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86078006P | 2006-11-21 | 2006-11-21 | |
| US60/860,780 | 2006-11-21 | ||
| US90274207P | 2007-02-21 | 2007-02-21 | |
| US60/902,742 | 2007-02-21 | ||
| PCT/US2007/085402 WO2008064321A2 (en) | 2006-11-21 | 2007-11-21 | Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010510323A JP2010510323A (ja) | 2010-04-02 |
| JP2010510323A5 true JP2010510323A5 (https=) | 2011-01-13 |
| JP5410293B2 JP5410293B2 (ja) | 2014-02-05 |
Family
ID=39386167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009538506A Expired - Fee Related JP5410293B2 (ja) | 2006-11-21 | 2007-11-21 | Ｇｍ−ｃｓｆアンタゴニストを用いて慢性炎症性疾患を治療する方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20080206241A1 (https=) |
| EP (2) | EP2101780B1 (https=) |
| JP (1) | JP5410293B2 (https=) |
| KR (1) | KR101517251B1 (https=) |
| CN (2) | CN105435223A (https=) |
| AU (1) | AU2007323541B2 (https=) |
| BR (1) | BRPI0719109A2 (https=) |
| CA (1) | CA2670288C (https=) |
| EA (1) | EA200900709A1 (https=) |
| ES (1) | ES2432173T3 (https=) |
| IL (1) | IL198829A0 (https=) |
| MX (1) | MX2009005398A (https=) |
| NZ (1) | NZ598345A (https=) |
| SG (1) | SG176503A1 (https=) |
| WO (1) | WO2008064321A2 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2101780B1 (en) | 2006-11-21 | 2013-10-09 | Kalobios Pharmaceuticals, Inc. | Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
| US8680019B2 (en) * | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
| WO2009023184A2 (en) * | 2007-08-10 | 2009-02-19 | Protelix, Inc. | Universal fibronectin type iii binding-domain libraries |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| TW200918553A (en) * | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| CN104072613A (zh) | 2007-11-13 | 2014-10-01 | Evec股份有限公司 | 与hGM-CSF结合的单克隆抗体及包含它的药物组合物 |
| US20090181020A1 (en) * | 2008-01-15 | 2009-07-16 | Kalobios Pharmaceuticals, Inc. | Methods of Treating Bone-Loss Disorders Using a GM-CSF Antagonist |
| EP2282757B1 (en) * | 2008-04-07 | 2013-05-22 | Kalobios Pharmaceuticals, Inc. | Neutralization of gm-csf for the treatment of heart failure |
| WO2009134805A2 (en) * | 2008-04-28 | 2009-11-05 | Kalobios Pharmaceuticals, Inc. | Antibodies to granulocyte-macrophage colony-stimulating factor |
| AU2015224416B2 (en) * | 2008-12-22 | 2017-04-20 | The University Of Melbourne | Osteoarthritis treatment |
| CN102271705A (zh) * | 2008-12-22 | 2011-12-07 | 墨尔本大学 | 骨关节炎治疗 |
| CA2747206C (en) | 2008-12-22 | 2018-04-24 | The University Of Melbourne | Pain treatment |
| WO2010093814A1 (en) * | 2009-02-11 | 2010-08-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a gm-csf antagonist |
| US8609101B2 (en) * | 2009-04-23 | 2013-12-17 | Theraclone Sciences, Inc. | Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies |
| US20120116059A1 (en) * | 2009-05-05 | 2012-05-10 | Morphosys Ag | Treatment For M Treatment For Multiple Sclerosis |
| CN103827143A (zh) * | 2011-07-06 | 2014-05-28 | 莫弗系统股份公司 | 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途 |
| MA37946B1 (fr) * | 2012-09-20 | 2018-09-28 | Morphosys Ag | Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde |
| KR20210021153A (ko) * | 2012-09-20 | 2021-02-24 | 모르포시스 아게 | 류마티스 관절염에 대한 치료 |
| AR093297A1 (es) * | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| US10745475B2 (en) * | 2013-08-30 | 2020-08-18 | Takeda Gmbh | Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics |
| JP6360696B2 (ja) * | 2014-03-18 | 2018-07-18 | 日本光電工業株式会社 | 血液検査装置および血液検査方法 |
| CN106456761A (zh) * | 2014-05-19 | 2017-02-22 | 免疫医疗有限公司 | 对类风湿关节炎的治疗 |
| WO2018031968A1 (en) * | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| SG11201901789WA (en) | 2016-09-19 | 2019-03-28 | I Mab | Anti-gm-csf antibodies and uses thereof |
| US11130805B2 (en) | 2017-10-02 | 2021-09-28 | Humanigen, Inc. | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
| US10899831B2 (en) | 2017-10-02 | 2021-01-26 | Humanigen, Inc. | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity |
| US10927168B2 (en) | 2017-10-02 | 2021-02-23 | Humanicen, Inc. | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab |
| AU2018345751A1 (en) * | 2017-10-02 | 2020-05-07 | Humanigen, Inc. | Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist |
| WO2020092850A1 (en) * | 2018-10-31 | 2020-05-07 | Humanigen, Inc. | Materials and methods for treating cancer |
| MX2022011111A (es) * | 2020-03-08 | 2023-03-02 | Humanigen Inc | Métodos para tratar infección de coronavirus y lesión pulmonar inducida por inflamación resultante. |
| AU2021392308A1 (en) * | 2020-12-04 | 2023-06-22 | CSL Innovation Pty Ltd | Methods for treating inflammatory skin conditions |
| WO2022192093A1 (en) * | 2021-03-08 | 2022-09-15 | Humanigen, Inc. | Methods for treating coronavirus infection and resulting inflammation-induced lung injury |
| CN116887856A (zh) * | 2022-01-20 | 2023-10-13 | 舒泰神（北京）生物制药股份有限公司 | 一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| EP0482086A1 (en) * | 1989-07-14 | 1992-04-29 | Schering Corporation | Antagonists of gm-csf derived from the carboxyl terminus |
| WO1994009149A1 (en) | 1990-08-10 | 1994-04-28 | Amrad Corporation Limited | Monoclonal antibody |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| MX336813B (es) | 1996-02-09 | 2016-02-02 | Abbvie Biotechnology Ltd | Anticuerpos humanos que ligan el tnfa humano. |
| US5770380A (en) | 1996-09-13 | 1998-06-23 | University Of Pittsburgh | Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7108852B2 (en) * | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| US7455836B2 (en) * | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
| JP2006500905A (ja) * | 2002-02-13 | 2006-01-12 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | ヒト化ｇｍ−ｃｓｆ抗体 |
| GB0224082D0 (en) * | 2002-10-16 | 2002-11-27 | Celltech R&D Ltd | Biological products |
| JP4912144B2 (ja) * | 2003-03-12 | 2012-04-11 | ジェネンテック， インコーポレイテッド | 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用 |
| TWI376370B (en) * | 2003-07-23 | 2012-11-11 | Synta Pharmaceuticals Corp | Compounds for inflammation and immune-related uses |
| EP1761561B1 (en) | 2004-01-20 | 2015-08-26 | KaloBios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| US7781617B2 (en) * | 2004-07-16 | 2010-08-24 | Kyorin Pharmaceutical Co., Ltd | Effective use method of medicaments and method of preventing expression of side effect |
| PT2343380T (pt) | 2004-11-16 | 2019-09-18 | Humanigen Inc | Permuta de cassetes da região variável de imunoglobulina |
| RU2447085C2 (ru) | 2005-05-18 | 2012-04-10 | МорфоСис АГ | Анти-gm-csf антитела и их применение |
| US20080305079A1 (en) * | 2006-01-06 | 2008-12-11 | Mount Sinai School Of Medicine Of New York University | Myeloid Suppressor Cells, Methods For Preparing Them, and Methods For Using Them For Treating Autoimmunity |
| US7741450B2 (en) * | 2006-02-08 | 2010-06-22 | Morphotek Inc. | Antibodies to GM-CSF |
| MX2008012291A (es) * | 2006-03-27 | 2009-01-12 | Medimmune Ltd | Miembro que enlaza al receptor gm-csf. |
| DE102006033837A1 (de) * | 2006-07-21 | 2008-01-31 | Medac Gesellschaft für klinische Spezialpräparate m.b.H | Konzentrierte Methotrexat-Lösungen |
| EP2101780B1 (en) | 2006-11-21 | 2013-10-09 | Kalobios Pharmaceuticals, Inc. | Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
-
2007
- 2007-11-21 EP EP07868831.4A patent/EP2101780B1/en not_active Revoked
- 2007-11-21 CN CN201510674256.5A patent/CN105435223A/zh active Pending
- 2007-11-21 WO PCT/US2007/085402 patent/WO2008064321A2/en not_active Ceased
- 2007-11-21 KR KR1020097012906A patent/KR101517251B1/ko not_active Expired - Fee Related
- 2007-11-21 EP EP11182971A patent/EP2402013A1/en not_active Withdrawn
- 2007-11-21 JP JP2009538506A patent/JP5410293B2/ja not_active Expired - Fee Related
- 2007-11-21 MX MX2009005398A patent/MX2009005398A/es active IP Right Grant
- 2007-11-21 US US11/944,162 patent/US20080206241A1/en not_active Abandoned
- 2007-11-21 BR BRPI0719109-0A2A patent/BRPI0719109A2/pt not_active IP Right Cessation
- 2007-11-21 NZ NZ598345A patent/NZ598345A/xx not_active IP Right Cessation
- 2007-11-21 ES ES07868831T patent/ES2432173T3/es active Active
- 2007-11-21 EA EA200900709A patent/EA200900709A1/ru unknown
- 2007-11-21 AU AU2007323541A patent/AU2007323541B2/en not_active Ceased
- 2007-11-21 CN CNA2007800495322A patent/CN101605547A/zh active Pending
- 2007-11-21 CA CA2670288A patent/CA2670288C/en not_active Expired - Fee Related
- 2007-11-21 SG SG2011085834A patent/SG176503A1/en unknown
-
2009
- 2009-05-19 IL IL198829A patent/IL198829A0/en unknown
-
2015
- 2015-05-14 US US14/712,627 patent/US20150246121A1/en not_active Abandoned